PTD4-apoptin protein therapy inhibits tumor growth in vivo

International Journal of Cancer

Volumn 124, Issue 12, 2009, Pages 2973-2981

  Sun, Jun ^a   Yan, Ying ^a   Wang, Xiao Ting ^a   Liu, Xiao Wen ^a   Peng, Dong Jun ^a,b   Wang, Min ^a   Tian, Jun ^a   Zong, Yi Qiang ^a   Zhang, Ying Hui ^b   Noteborn, Mathieu H M ^a,b   Qu, Shen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cell death; Cervix tumor; Gastric tumor; Hepatocarcinoma; PTD4 mediated apoptin protein delivery

Indexed keywords

APOPTIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; PROTEIN PTD4; RECOMBINANT PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CAPSID PROTEIN; CARRIER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL NUCLEUS; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOPLASM; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; STOMACH CARCINOMA; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL FRACTIONATION; CLONOGENIC ASSAY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; GENETICS; LIVER CELL; LIVER TUMOR; METABOLISM; NICK END LABELING; NUCLEAR LOCALIZATION SIGNAL; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; UTERINE CERVIX TUMOR;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CAPSID PROTEINS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL NUCLEUS; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FEMALE; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR LOCALIZATION SIGNALS; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS; SUBCELLULAR FRACTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 65649090146     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24279     Document Type: Article

References (39)

1. Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 2006;11:167-175 (Pubitemid 44087114)
2. Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Med Chem 2005;1:125-129
3. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006;5:10-19. (Pubitemid 43234971)
4. Alvisi G, Poon IK, Jans DA. Tumor-specific nuclear targeting: promises for anti-cancer therapy. Drug Resist Update 2006;9:40-50. (Pubitemid 43928804)
5. Noteborn MHM. Apoptin acts as a tumor-specific killer: potentials for an anti-tumor therapy. Cell Mol Biol 2005;51:49-60. (Pubitemid 43093391)
6. Rohn JL, Noteborn MHM. The viral death effector apoptin reveals tumor-specific processes. Apoptosis 2004;9:315-322 (Pubitemid 38981505)
7. Van der Eb MM, Pietersen AM, Speetjens FM, Kuppen PJ, van de Velde CJ, Noteborn MHM, Hoeben RC. Gene therapy with apoptin induces regression of xenografted human hepatomas. Cancer Gene Ther 2002;9:53-61. (Pubitemid 34052854)
8. Lian H, Jin N, Li X, Mi Z, Zhang J, Sun B, Li X, Zheng H, Li P. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin. Cancer Immunol Immunother 2007;56:181-192 (Pubitemid 44833092)
9. Liu X, Zeidan YH, Elojeimy S, Holman DH, El-Zawahry AM, Guo GW, Bielawska A, Bielawski J, Szulc Z, Rubinchick S, Dong JY, Keane TE, et al. Involvements of sphingolipids in apoptin-induced cell killing. Mol Ther 2006;14:627-636 (Pubitemid 44480757)
10. Peng DJ, Sun J, Wang YZ, Tian J, Zhang YH, Noteborn MHM, Qu S. Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene to the hepatic asiaglycorprotein receptor. Cancer Gene Ther 2007;14:66-73. (Pubitemid 44952235)
11. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006;16:879-886 (Pubitemid 44764197)
12. Bagi CM. Targeting of therapeutic agents to bone to treat metastatic cancer. Adv Drug Deliv Rev 2005;57:995-1010. (Pubitemid 40692289)
13. Guelen B, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004;23:1153-1165 (Pubitemid 38269969)
14. Ho A, Schwarze SR, Ermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 2001;61:474-477 (Pubitemid 32128600)
15. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating protein and peptides. Adv Drug Deliv Rev 2005;57:637-651 (Pubitemid 40255564)
16. Sun J, Wang YZ, Zong YQ, Qu S. Cloning of chicken anemia virus vp3 gene and apoptosis inductive effect of vp3 gene in vitro. J Huazhong Uni Sci Technol [Med Sci] 2003;23:329-331
17. Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS. Induction of antigen-specific CTL by recombinant HIV transactivating fusion protein-pulsed human monocyte-derived dendritic cells. J Immunol 2003;170:1291-1298 (Pubitemid 36139495)
18. Kooistra K, Zhang Y-H, Noteborn MHM. Viral elements sense tumorigenic processes: approaching selective cancer therapy. Mini Rev Med Chem 2007;7:1155-1165 (Pubitemid 350200222)
19. Backendorf C, De Boer B, Visser M, Voskamp P, Zhang Y-H, Noteborn MHM. Apoptin: potential as an anti-tumor therapy. Annu Rev Pharmacol Toxicol 2008;48:143-169
20. Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2005;2:43-51. (Pubitemid 40123882)
21. Davis BG, Robinson MA. Drug delivery systems based on sugar-macromolecule conjugates. Curr Opin Drug Discov Dev 2002;5:29-34. (Pubitemid 35012714)
22. Danen-Van Oorschot AAAM, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JHF, Backendorf C, Quax PH, Van der Eb AJ, Noteborn MHM. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997;94:5843-5847 (Pubitemid 27241859)
23. Heilman DW, Teodoro JG, Green MR. Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J Virol 2006;80:7535-7545 (Pubitemid 44092575)
24. Chada S, Ramesh R. Apoptin studies illuminate intersection between lipidomics and tumor suppressors. Mol Ther 2007;15:7-9. (Pubitemid 46043642)
25. Lee YH, Cheng CM, Chang YF, Wang TY, You CY. Apoptin 108 phosphorylation is not required for its tumor-specific nuclear localization but partially affects its apoptotic activity. Biochem Biophys Res Commun 2007;354:391-395 (Pubitemid 46172452)
26. Zhang Y-H, Leliveld SR, Kooistra K, Molenaar C, Rohn JL, Tanke HJ, Abrahams JP, Noteborn MHM. Recombinant apoptin multimers kill tumor cells but are non-toxic and epitope-shielded in a normal-cell-specific fashion. Exp Cell Res 2003;289:36-46. (Pubitemid 36993835)
27. Poon IK, Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res 2005;65:7059-7064 (Pubitemid 41161232)
28. Rohn JL, Zhang Y-H, Leliveld SR, Danen-van Oorschot AAAM, Henriquez NV, Abrahams JP, Noteborn MHM. Relevance of apoptin's integrity for its functional behavior. J Virol 2005;79:1337-1338 (Pubitemid 40053917)
29. Pietersen AM. Preclinical studies with apoptin. PhD Thesis, Erasmus University, Rotterdam, The Netherlands, 2003.
30. Liu X, Elojeimy S, El-Zawahry AM, Holman DH, Bielawska A, Bielwaski J, Rubinchik S, Guo GW, Dong JY, Keane T, Hannun YA, Tavassoli M, et al. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther 2006;14:637-646 (Pubitemid 44480756)
31. Olijslagers S, Zhang Y-H, Backendorf C, Noteborn MHM. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 2007;100:127-131 (Pubitemid 46146717)
32. Zhang Y-H, Olijslagers S, Backendorf C, Noteborn MHM. Apoptin close-ups: perspectives towards novel therapies. J Med Mol Biol 2006;3:401-406
33. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci 2006;27:311-319 (Pubitemid 43143256)
34. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57:579-596 (Pubitemid 40255562)
35. Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, Leachman SA, Lee RM, Grossman D. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable survivin antagonist. Oncogene 2006;25:6968-6974 (Pubitemid 44684837)
36. Jiang B, Ma Y, Wang J, Tao X, Wei D. The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis. Mol Biol Rep 2008;35:1-8.
37. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 2007;14:1763-1771 (Pubitemid 46790997)
38. Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, Dowdy SF. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res 2005;65:10646-10650 (Pubitemid 41713328)
39. Han SX, Ma JL, Lv Y, Huang C, Liang HH, Duan KM. Secretory transactivating transcription-apoptin fusion protein induces apoptosis in hepatocellular carcinoma HepG2 cells. World J Gastroenterol 2008;14:3642-3649